Advertisement
UK markets close in 2 hours 3 minutes

  • FTSE 100

    7,837.99
    -39.06 (-0.50%)
     

  • FTSE 250

    19,322.26
    -128.41 (-0.66%)
     

  • AIM

    743.05
    -2.24 (-0.30%)
     

  • GBP/EUR

    1.1679
    -0.0004 (-0.04%)
     

  • GBP/USD

    1.2462
    +0.0024 (+0.19%)
     

  • Bitcoin GBP

    51,928.58
    +1,827.03 (+3.65%)
     

  • CMC Crypto 200

    1,333.42
    +20.80 (+1.61%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CRUDE OIL

    82.11
    -0.62 (-0.75%)
     

  • GOLD FUTURES

    2,388.70
    -9.30 (-0.39%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,735.10
    -102.30 (-0.57%)
     

  • CAC 40

    8,020.58
    -2.68 (-0.03%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Novartis, Pfizer cut prices to win UK approval for cancer drugs

Reuters - UK Focus

LONDON, Nov 10 (Reuters) - Novartis (LSE: 0QLR.L - news) and Pfizer have won approval for two cancer drugs to be used routinely on Britain's National Health Service after offering bigger price discounts.

The National Institute for Health and Care Excellence (NICE (Milan: NICE.MI - news) ) said on Thursday its draft guidance now recommended Novartis' Afinitor for certain breast cancer patients and Pfizer (NYSE: PFE - news) 's Xalkori in lung cancer following the undisclosed "larger" discounts.

The move comes as NICE reappraises all drugs covered by the Cancer Drugs Fund, which was overhauled earlier this year.

Japan's Eisai last week won a similar green light for its breast cancer drug Halaven after cutting the price for Britain's state health service. (Reporting by Ben Hirschler; Editing by Mark Potter)